Comparison · NCT00756613-ec10fc87
465 VADT Participants - Standard vs 465 VADT Participants -Intensive: The Long Term Effects of Intensive Glycemic Control in Type 2 Diabetes on the Secondary Outcome Total Mortality.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. 465 VADT Participants - Standard vs 465 VADT Participants -Intensive: The Long Term Effects of Intensive Glycemic Control in Type 2 Diabetes on the Secondary Outcome Total Mortality. Trial comparisons, record NCT00756613-ec10fc87. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00756613-ec10fc87
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.407 | 0.375 | 0.44 | wilson | |
| Risk in group 2 | 0.422 | 0.39 | 0.454 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0144 | -0.0599 | 0.0312 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.966 | 0.865 | 1.08 | log | |
| Odds ratio, group 1 over group 2 | 0.942 | 0.781 | 1.14 | log | |
| Number needed to treat, for one fewer participant with the outcome on 465 VADT Participants - Standard than on 465 VADT Participants -Intensive | 69.4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | 465 VADT Participants - Standard | The participants had previously participated in the VADT Cooperative Studies Program (CSP) #465 study in standard treatment group. | 366 | 899 | OG000 |
| Group 2 | 465 VADT Participants -Intensive | The participants had previously participated in the VADT Cooperative Studies Program (CSP) #465 study in the intensive group. | 376 | 892 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- The Long Term Effects of Intensive Glycemic Control in Type 2 Diabetes on the Secondary Outcome Total Mortality.
- Description
The major secondary end-point of cardiovascular (CV) mortality will measure the cause of death (end-stage renal disease, amputation for either ischemic or non-ischemic gangrene, CV-related death, or nonfatal myocardial infarction (MI), stroke, or new congestive heart failure (CHF)) retrieved by the National Death Index (NDI). Survival analysis will analyzed by time of event to death.
- Time frame
- 15 years
- Population
Total number of participants reflect all that participated in the VA Cooperative Studies Program (CSP) #465 study, Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT) NCT00032487, but censored those who refused to consent to 465 follow-up study or died or withdrew from the study.
Source ClinicalTrials.gov
Trial
- Title
- The VA Diabetes Trial Follow-up Study (VADT-FS)
- NCT number
- NCT00756613
- Phases
- Conditions
- Diabetes, Glycemic Control
- Interventions
- Lead sponsor
- VA Office of Research and Development
- Results first posted
- 2019-06-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00756613?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00756613-ec10fc87